C4 Therapeutics (NASDAQ:CCCC) announced on April 9, 2026, a significant expansion of its decade-long relationship with Roche, entering into a new collaboration to advance the emerging field of Degrader-Antibody Conjugates (DACs).
Chevron (NYSE:CVX) and project operator Occidental announced on April 9, 2026, a significant oil discovery at the Bandit prospect, located in the deepwater Gulf of America.
Galmed Pharmaceuticals (NASDAQ:GLMD) announced on April 9, 2026, a significant technological breakthrough with the development of a brain-penetrating formulation of its lead compound, Aramchol.
ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology firm, reported on April 9, 2026, that preliminary net product revenue for the first quarter reached approximately $44.2 million.
First Majestic Silver (NYSE:G) reported on April 9, 2026, that consolidated ore processed at its Mexican operations rose 12% year-over-year to 1,059,333 tonnes in the first quarter.
Neogen (NASDAQ:NEOG), a global leader in food and animal safety, reported on April 9, 2026, that it has raised its full-year revenue guidance following a third-quarter performance marked by steady gains in its core food safety business and significant progress on strategic portfolio realignments.
Polestar (NASDAQ:PSNY), the Swedish electric performance car manufacturer, reported on April 9, 2026, that estimated retail sales for the first quarter reached 13,126 vehicles.
BlackBerry (NYSE:BB) reported its fiscal fourth-quarter and full-year 2026 financial results on April 9, 2026, highlighting a significant turnaround in profitability driven by record demand for its automotive and embedded software division.
The Buckle (NYSE:BKE) announced on April 9, 2026, a robust performance for the five-week fiscal month ended April 4, 2026, with net sales climbing 8.2% to $118 million.
Eli Lilly and Company (NYSE:LLY) achieved a significant milestone in the competitive metabolic health market as its once-daily oral medication, Foundayo (orforglipron), became available in U.S. retail pharmacies on April 9, 2026.
IDEAYA Biosciences (NASDAQ:IDYA), a precision medicine oncology company, announced on April 9, 2026, that it has entered into a clinical collaboration agreement with AstraZeneca (NASDAQ:AZN) to study a potential first-in-class combination treatment for extensive-stage small cell lung cancer (SCLC).
Prologis (NYSE:PLD), the global leader in logistics real estate, and La Caisse de dépôt et placement du Québec (CDPQ) announced on April 9, 2026, the launch of Prologis Logistics Investment Venture Europe (PLIVE).
